Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	63
Overall Study	STARTED	Atacicept 25 mg	63
Overall Study	STARTED	Atacicept 75 mg	64
Overall Study	STARTED	Atacicept 150 mg	65
Overall Study	Treated	Placebo	63
Overall Study	Treated	Atacicept 25 mg	63
Overall Study	Treated	Atacicept 75 mg	63
Overall Study	Treated	Atacicept 150 mg	65
Overall Study	COMPLETED	Placebo	23
Overall Study	COMPLETED	Atacicept 25 mg	21
Overall Study	COMPLETED	Atacicept 75 mg	21
Overall Study	COMPLETED	Atacicept 150 mg	25
Overall Study	NOT COMPLETED	Placebo	40
Overall Study	NOT COMPLETED	Atacicept 25 mg	42
Overall Study	NOT COMPLETED	Atacicept 75 mg	43
Overall Study	NOT COMPLETED	Atacicept 150 mg	40

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00642902/flow